Nutex Health (NUTX) Projected to Release Quarterly Earnings on Thursday

Nutex Health (NASDAQ:NUTX) is expected to be announcing its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect Nutex Health to post earnings of $5.54 per share and revenue of $214.82 million for the quarter. Individuals can check the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Friday, November 6, 2026 at 10:30 AM ET.

Nutex Health (NASDAQ:NUTX) last released its quarterly earnings data on Thursday, August 6th. The company reported $9.38 earnings per share for the quarter, beating the consensus estimate of $4.95 by $4.43. Nutex Health had a return on equity of 39.74% and a net margin of 21.25%. The business had revenue of $210.75 million for the quarter, compared to analysts’ expectations of $215.03 million. On average, analysts expect Nutex Health to post $27.58 EPS for the current fiscal year and $28.70 EPS for the next fiscal year.

Nutex Health Price Performance

Shares of NUTX opened at $212.63 on Thursday. The stock has a 50 day simple moving average of $202.62 and a 200 day simple moving average of $150.48. Nutex Health has a 52-week low of $83.99 and a 52-week high of $226.16. The company has a debt-to-equity ratio of 0.59, a quick ratio of 4.96 and a current ratio of 5.00. The firm has a market capitalization of $1.46 billion, a PE ratio of 8.35 and a beta of 0.55.

Insider Buying and Selling at Nutex Health

In other news, Director Scott Saunders sold 203 shares of the firm’s stock in a transaction that occurred on Friday, September 18th. The shares were sold at an average price of $214.25, for a total transaction of $43,492.75. Following the completion of the transaction, the director directly owned 400 shares of the company’s stock, valued at $85,700. This trade represents a 33.67% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 44.68% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on NUTX shares. LADENBURG THALM/SH SH started coverage on shares of Nutex Health in a research note on Monday. They issued a “buy” rating and a $336.00 price target on the stock. Zacks Research lowered shares of Nutex Health from a “strong-buy” rating to a “hold” rating in a report on Tuesday, October 6th. B. Riley Financial restated a “buy” rating on shares of Nutex Health in a report on Friday, September 4th. Wall Street Zen upgraded Nutex Health from a “hold” rating to a “buy” rating in a report on Saturday, October 3rd. Finally, Weiss Ratings raised Nutex Health from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Tuesday, October 6th. Four investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, Nutex Health presently has an average rating of “Moderate Buy” and an average price target of $323.67.

Nutex Health Company Profile

Nutex Health, Inc (NASDAQ:NUTX) is a physician-led healthcare services company that operates an integrated network of hospitals, medical facilities and physician practices in the United States. The company focuses on providing convenient, community-based care through its micro-hospitals and other healthcare locations.

Its hospital operations generally include emergency services, inpatient care, diagnostic testing and outpatient treatment. Nutex also operates physician networks and supports primary care and specialty providers.